Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Diabetes mellitus4971 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A50028 | 35558979 | Transl Pediatr | Whole-exome sequencing establishes a diagnosis of Alstrom syndrome: a case report. | 2022 | Details |
| A50031 | 35557545 | Front Cardiovasc Med | Non-alcoholic Fatty Liver Disease Is Associated With Cardiovascular Outcomes in Subjects With Prediabetes and Diabetes: A Prospective Community-Based Cohort Study. | 2022 | Details |
| A50045 | 35547362 | PPAR Res | Molecular Dynamics Simulation and Essential Dynamics of Deleterious Proline 12 Alanine Single-Nucleotide Polymorphism in PPARγ2 Associated with Type 2 Diabetes, Cardiovascular Disease, and Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A50062 | 35538431 | BMC Cardiovasc Disord | Effect of resveratrol supplementation on hepatic steatosis and cardiovascular indices in overweight subjects with type 2 diabetes: a double-blind, randomized controlled trial. | 2022 | Details |
| A50071 | 35535099 | J Clin Exp Hepatol | Prevalence of Risk Factors for Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Patients With Cryptogenic Cirrhosis. | 2021 | Details |
| A50073 | 35535092 | J Clin Exp Hepatol | Diabetes Mellitus Increases the Risk of Significant Hepatic Fibrosis in Patients With Non-alcoholic Fatty Liver Disease. | 2021 | Details |
| A50076 | 35535068 | J Clin Exp Hepatol | FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort. | 2021 | Details |
| A50081 | 35534202 | J Clin Pathol | Postmortem survey of haemoglobin A1c, non-alcoholic steatohepatitis and liver fibrosis within a general population. | 2022 | Details |
| A50093 | 35530830 | Cureus | Hepatic Glycogenosis: An Underdiagnosed Entity? | 2022 | Details |
| A50095 | 35528989 | J Clin Transl Hepatol | Glutaminolysis-ammonia-urea Cycle Axis, Non-alcoholic Fatty Liver Disease Progression and Development of Novel Therapies. | 2022 | Details |
| A50096 | 35528987 | J Clin Transl Hepatol | Coagulation and Endothelial Dysfunction Associated with NAFLD: Current Status and Therapeutic Implications. | 2022 | Details |
| A50099 | 35528971 | J Clin Transl Hepatol | Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver. | 2021 | Details |
| A50102 | 35528151 | Acta Clin Croat | CROATIAN GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE. | 2021 | Details |
| A50107 | 35525248 | Lancet Gastroenterol Hepatol | Community pathways for the early detection and risk stratification of chronic liver disease: a narrative systematic review. | 2022 | Details |
| A50123 | 35512974 | Fertil Steril | Nonalcoholic fatty liver disease and obstructive sleep apnea in women with polycystic ovary syndrome. | 2022 | Details |
| A50134 | 35508191 | Am J Physiol Cell Physiol | The role of mitochondria in the pathophysiology and treatment of common metabolic diseases in humans. | 2022 | Details |
| A50139 | 35506136 | Radiol Cardiothorac Imaging | Hepatosteatosis and Atherosclerotic Plaque at Coronary CT Angiography. | 2022 | Details |
| A50141 | 35504499 | Nitric Oxide | Hydrogen sulfide potentiates the protective effects of nitrite against myocardial ischemia-reperfusion injury in type 2 diabetic rats. | 2022 | Details |
| A50149 | 35503178 | Adv Exp Med Biol | Cholesterol Metabolism in Chronic Kidney Disease: Physiology, Pathologic Mechanisms, and Treatment. | 2022 | Details |
| A50150 | 35503172 | Adv Exp Med Biol | De Novo Sphingolipid Biosynthesis in Atherosclerosis. | 2022 | Details |
| A50164 | 35495903 | Front Nutr | Amino Acid and Fatty Acid Metabolism Disorders Trigger Oxidative Stress and Inflammatory Response in Excessive Dietary Valine-Induced NAFLD of Laying Hens. | 2022 | Details |
| A50172 | 35491150 | Yakugaku Zasshi | [Metabolism-dependent Vascular Pathophysiology in Adult Diseases]. | 2022 | Details |
| A50175 | 35490415 | West Afr J Med | Clinical Correlates of Non-alcoholic Steatohepatitis in Nigerian Patients with Metabolic Syndrome. | 2022 | Details |
| A50181 | 35487606 | Clin Liver Dis | The Interplay Between Nonalcoholic Fatty Liver Disease and Kidney Disease. | 2022 | Details |
| A50182 | 35486350 | Ir J Med Sci | Reduced and more appropriate referrals of patients with type 2 diabetes using liver stiffness measurement compared to FIB-4. | 2022 | Details |
| A50183 | 35486295 | J Genet Eng Biotechnol | Sociodemographic and genetic determinants of nonalcoholic fatty liver disease in type 2 diabetes mellitus patients. | 2022 | Details |
| A50213 | 35471616 | Wien Klin Wochenschr | New inflammatory biomarkers (lymphocyte and monocyte percentage to high-density lipoprotein cholesterol ratio and lymphocyte to monocyte percentage ratio) and their association with some cardiometabolic diseases : Results from a large Kurdish cohort study in Iran. | 2022 | Details |
| A50223 | 35465684 | Hypertension | Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors. | 2022 | Details |
| A50231 | 35463855 | Diabetol Int | The epidemiology, clinical, biochemical, immunological and radiological features of youth onset type 2 diabetes mellitus in the state of Qatar. | 2021 | Details |
| A50239 | 35462330 | Biomed Pharmacother | Update of Indoles: Promising molecules for ameliorating metabolic diseases. | 2022 | Details |
| A50248 | 35457142 | Int J Mol Sci | Role of Branched-Chain Amino Acid Metabolism in Type 2 Diabetes, Obesity, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A50249 | 35457120 | Int J Mol Sci | PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients. | 2022 | Details |
| A50251 | 35455663 | J Pers Med | Non-Alcoholic Fatty Liver Disease and the Risk of Diabetes Mellitus by Menopausal Status: A Nationwide Cohort Study. | 2022 | Details |
| A50255 | 35453849 | Diagnostics (Basel) | Clinical and Laboratory Characteristics of Normal Weight and Obese Individuals with Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A50256 | 35453652 | Biomedicines | Potential Therapeutic Targets and Promising Agents for Combating NAFLD. | 2022 | Details |
| A50259 | 35451807 | Curr Med Sci | Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice. | 2022 | Details |
| A50265 | 35449683 | Cureus | Does Samoa Have Adequate Policies to Reduce Obesity and Obesity-Related Disease? | 2022 | Details |
| A50272 | 35448486 | Metabolites | Nonalcoholic Fatty Liver Disease and Endocrine Axes-A Scoping Review. | 2022 | Details |
| A50278 | 35444985 | Front Public Health | A Machine Learning Based Framework to Identify and Classify Non-alcoholic Fatty Liver Disease in a Large-Scale Population. | 2022 | Details |
| A50280 | 35444436 | Diabetes Metab Syndr Obes | Association Between the Risk of Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease. | 2022 | Details |
| A50283 | 35443534 | J Assoc Physicians India | Correlation Between Carotid Intima Media Thickness and Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A50284 | 35443531 | J Assoc Physicians India | Clinical Characteristics and Metabolic Profiles of Non-Alcoholic Fatty Liver Disease (NAFLD) in Lean Patients and Their Comparison with Obese and Overweight NAFLD. | 2022 | Details |
| A50285 | 35443488 | J Assoc Physicians India | Comparison of Novel Fibrosis Index (NFI) with Aspartate aminotransferase to platelet ratio index (APRI) in Type II Diabetes mellitus patients with Non alcoholic fatty liver disease and fibrosis (NAFLD). | 2022 | Details |
| A50287 | 35443467 | J Assoc Physicians India | Assessment of liver fibrosis using non-invasive screening tools in individuals with diabetes mellitus and metabolic syndrome. | 2022 | Details |
| A50297 | 35440282 | Int J Circumpolar Health | Non-alcoholic fatty liver disease in patients with type 2 diabetes in Greenland: a register-based cross-sectional study. | 2022 | Details |
| A50304 | 35437952 | EMBO Mol Med | When fat meets the gut-focus on intestinal lipid handling in metabolic health and disease. | 2022 | Details |
| A50305 | 35437902 | J Diabetes Investig | Combined evaluation of Fibrosis-4 index and fatty liver for stratifying the risk for diabetes mellitus. | 2022 | Details |
| A50321 | 35434590 | JHEP Rep | Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease. | 2022 | Details |
| A50334 | 35430025 | J Clin Lipidol | JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk. | 2022 | Details |
| A50335 | 35429980 | Cardiovasc Diabetol | The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study. | 2022 | Details |
| A50343 | 35428219 | BMC Endocr Disord | Value of the triglyceride glucose index combined with body mass index in identifying non-alcoholic fatty liver disease in patients with type 2 diabetes. | 2022 | Details |
| A50344 | 35427804 | Ann Hepatol | Non-alcoholic fatty liver disease prevalence in Latin America: A systematic review and meta-analysis. | 2022 | Details |
| A50348 | 35421921 | BMC Microbiol | Characterization of microbiome and metabolite analyses in patients with metabolic associated fatty liver disease and type II diabetes mellitus. | 2022 | Details |
| A50359 | 35418240 | Arterioscler Thromb Vasc Biol | Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. | 2022 | Details |
| A50369 | 35413987 | BMC Health Serv Res | Implementing the right care in the right place at the right time for non-alcoholic fatty liver disease (NAFLD-RRR study): a study protocol for a community care pathway for people with type 2 diabetes. | 2022 | Details |
| A50377 | 35412016 | Clin Obes | The impact of health status, diet and lifestyle on non-alcoholic fatty liver disease: Narrative review. | 2022 | Details |
| A50386 | 35409028 | Int J Mol Sci | SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A50390 | 35407364 | J Clin Med | Improvement of Type 2 Diabetes Mellitus and Attenuation of NAFLD Are Associated with the Success of Obesity Therapy. | 2022 | Details |
| A50404 | 35403438 | Am J Physiol Endocrinol Metab | Loss of low-molecular-weight protein tyrosine phosphatase shows limited improvement in glucose tolerance but causes mild cardiac hypertrophy in mice. | 2022 | Details |
| A50433 | 35394120 | Obesity (Silver Spring) | Response to: "Nonalcoholic fatty liver disease in diabetes: Overlooked or just ignored?" | 2022 | Details |
| A50445 | 35388643 | Endocrinol Diabetes Metab | Adipose tissue measurement in clinical research for obesity, type 2 diabetes and NAFLD/NASH. | 2022 | Details |
| A50447 | 35387749 | Eur J Intern Med | Non-alcoholic fatty liver disease: identical etiologic factors in patients with type 1 and type 2 diabetes. | 2022 | Details |
| A50449 | 35386158 | Cureus | Assessment of Liver Fibrosis Using Non-invasive Screening Tools in Individuals With Diabetes Mellitus and Metabolic Syndrome. | 2022 | Details |
| A50468 | 35378329 | Mol Metab | Hepatocyte-specific activity of TSC22D4 triggers progressive NAFLD by impairing mitochondrial function. | 2022 | Details |
| A50471 | 35377094 | Wien Med Wochenschr | [Current aspects on nutrition in hypercholesterolemia]. | 2022 | Details |
| A50473 | 35373513 | Obesity (Silver Spring) | Nonalcoholic fatty liver disease in diabetes: Overlooked or just ignored? | 2022 | Details |
| A50480 | 35369480 | Front Microbiol | Targeting Gut Microbiota With Natural Polysaccharides: Effective Interventions Against High-Fat Diet-Induced Metabolic Diseases. | 2022 | Details |
| A50486 | 35367353 | Biochim Biophys Acta Mol Cell Biol Lipids | Nudix hydrolase NUDT19 regulates mitochondrial function and ATP production in murine hepatocytes. | 2022 | Details |
| A50493 | 35365931 | Hepatol Commun | Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017-2018 transient elastography data and application of machine learning. | 2022 | Details |
| A50508 | 35359191 | Diabetologia | Long-term outcomes of dietary carbohydrate restriction for HbA1c reduction in type 2 diabetes mellitus are needed. Reply to Kang J and Ma E [letter]. | 2022 | Details |
| A50509 | 35359014 | Exp Clin Endocrinol Diabetes | Cigarette Smoking Increases the Risk of Type 2 Diabetes Mellitus in Patients with Non-alcoholic Fatty Liver Disease: A Population-Based Cohort Study. | 2022 | Details |
| A50515 | 35356372 | Oman Med J | Prevalence of Non-alcoholic Fatty Liver Disease among Patients with Diabetes Mellitus Attending Primary Health Care Centers in Bahrain. | 2022 | Details |
| A50516 | 35355562 | Front Endocrinol (Lausanne) | Case Report: Hepatic Adenomatosis in a Patient With Prader-Willi Syndrome. | 2022 | Details |
| A50521 | 35354697 | Endocr J | Increased brain-derived neurotrophic factor in the serum of persons with nonalcoholic fatty liver disease. | 2022 | Details |
| A50522 | 35354641 | BMJ Health Care Inform | Machine learning using longitudinal prescription and medical claims for the detection of non-alcoholic steatohepatitis (NASH). | 2022 | Details |
| A50523 | 35354619 | BMJ Open | Validation of type 2 diabetes subgroups by simple clinical parameters: a retrospective cohort study of NHANES data from 1999 to 2014. | 2022 | Details |
| A50529 | 35352691 | Eur J Gastroenterol Hepatol | Nonalcoholic fatty liver disease: opinions, population served, and management from a sample of French hepato(gastroentero)logists (PERSEPT study). | 2022 | Details |
| A50536 | 35349482 | J Clin Invest | Targeting hepatic kisspeptin receptor ameliorates nonalcoholic fatty liver disease in a mouse model. | 2022 | Details |
| A50543 | 35347118 | Cell Death Dis | Hepatic deficiency of selenoprotein S exacerbates hepatic steatosis and insulin resistance. | 2022 | Details |
| A50554 | 35343663 | Minerva Gastroenterol (Torino) | Associations between muscle mass, strength, and performance and non-alcoholic fatty liver disease. | 2022 | Details |
| A50565 | 35338555 | Liver Int | Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction-associated fatty liver disease in Korea. | 2022 | Details |
| A50567 | 35338446 | Diabetes Ther | Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications. | 2022 | Details |
| A50568 | 35338048 | BMJ Open Gastroenterol | Metabolic dysfunction-related liver disease as a risk factor for cancer. | 2022 | Details |
| A50571 | 35334964 | Nutrients | Selected Organ and Endocrine Complications According to BMI and the Metabolic Category of Obesity: A Single Endocrine Center Study. | 2022 | Details |
| A50578 | 35334125 | Hepatology | Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease. | 2022 | Details |
| A50579 | 35333917 | J Clin Endocrinol Metab | A Simple Test to Identify the Risk of NASH and Cirrhosis in People With Obesity or Diabetes: The Time to Screen Is Now. | 2022 | Details |
| A50582 | 35333295 | Alcohol Alcohol | Alcohol Consumption: Medical Implications, the Liver and Beyond. | 2022 | Details |
| A50584 | 35332833 | Postgrad Med | Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population. | 2022 | Details |
| A50601 | 35328527 | Int J Mol Sci | SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection. | 2022 | Details |
| A50602 | 35328503 | Int J Mol Sci | The Endocannabinoid System and Physical Activity-A Robust Duo in the Novel Therapeutic Approach against Metabolic Disorders. | 2022 | Details |
| A50607 | 35327501 | Biomedicines | Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19. | 2022 | Details |
| A50611 | 35326230 | Antioxidants (Basel) | Combination Effects of Metformin and a Mixture of Lemon Balm and Dandelion on High-Fat Diet-Induced Metabolic Alterations in Mice. | 2022 | Details |
| A50633 | 35319691 | Rev Med Chil | [Non-alcoholic fatty liver disease in type 2 diabetes: a joint statement of the Chilean Hepatology and Diabetology Societies]. | 2021 | Details |
| A50648 | 35316465 | Curr Diab Rep | Implementation of Cardiometabolic Centers and Training Programs. | 2022 | Details |
| A50652 | 35314166 | Biochem Pharmacol | Potential role of mitochondria-associated endoplasmic reticulum membrane proteins in diseases. | 2022 | Details |
| A50654 | 35312970 | Diabetes Ther | Additional Effect of Luseogliflozin on Semaglutide in Nonalcoholic Steatohepatitis Complicated by Type 2 Diabetes Mellitus: An Open-Label, Randomized, Parallel-Group Study. | 2022 | Details |
| A50659 | 35311663 | Metabolism | Sterol carrier protein 2 in lipid metabolism and non-alcoholic fatty liver disease: Pathophysiology, molecular biology, and potential clinical implications. | 2022 | Details |
| A50669 | 35307907 | J Biochem Mol Toxicol | Antioxidant for treatment of diabetic complications: A meta-analysis and systematic review. | 2022 | Details |
| A50672 | 35307033 | BMC Med | Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study). | 2022 | Details |
| A50680 | 35304846 | Lancet HIV | Diagnosis of liver fibrosis in ageing patients with HIV at risk for non-alcoholic fatty liver disease in Italy and Canada: assessment of a two-tier pathway. | 2022 | Details |